Treatment with emodin (1,3,8‐trihydroxy‐6‐methylanthraquinone) (Bruney et al., 2016), promotes a MET process by targeting ILK in ovarian cancer (Lu et al., 2016) and endometrial sarcoma cells (Zheng et al., 2016), in addition to reducing EMT through the ILK/AKT/mTOR signaling pathway in breast cancer cells (Ma et al., 2016) (Fig. 2). Here, ILK is linked to breast carcinoma.